Labetalol is a combined alpha and beta blocker used to treat high blood pressure, including the severe hypertension and preeclampsia that can come up during pregnancy. It is common in labor and delivery units, emergency departments, and primary care. It is also one of the medications that has shown up repeatedly in published reports as a cause of a false positive amphetamine or methamphetamine result on a urine immunoassay drug screen. This article explains what the screening chemistry actually does, what the published literature says about labetalol specifically, and why a positive immunoassay is never the end of the story.
Screening immunoassay versus confirmation testing
Most urine drug tests used in hospitals, clinics, and workplaces start with an immunoassay. An immunoassay uses antibodies designed to bind to a target drug class, such as amphetamines. The antibody is not perfectly selective. It can also bind to other molecules that share part of the same chemical shape, which is called cross reactivity. That is how a medication that is not an amphetamine can still trigger a positive screen on an amphetamine panel. The National Library of Medicine's drug testing overview explains that an initial screening result that comes back positive is normally followed by a second, more selective confirmation test, and that false positives on the first test can happen because of cross reaction with other substances in the body.
The confirmation method is chromatography paired with mass spectrometry, commonly written as GC/MS or LC-MS/MS. This method identifies the exact molecule present rather than reacting to a family shape, so it does not share the same cross reactivity problem. If a sample is truly negative for amphetamine or methamphetamine, confirmation testing will report it as negative even if the screening immunoassay flagged it as positive.
What the published literature says about labetalol
A case series published in a peer reviewed obstetrics journal and indexed on PubMed described three pregnant patients taking labetalol whose urine toxicology screens came back positive for amphetamines on the initial immunoassay. In each case, confirmation testing did not find amphetamine or methamphetamine in the sample. You can read the case report on the National Library of Medicine's PubMed listing for the study.
An earlier analytical chemistry study, also indexed on PubMed, traced the cause to a labetalol metabolite whose structure is close enough to the amphetamine class that it can bind the antibody used in some immunoassay kits. That study is available through the PubMed record for the labetalol metabolite research. Not every amphetamine immunoassay kit on the market necessarily reacts the same way, since manufacturers use different antibodies and cutoff concentrations, but the mechanism described in these two sources is consistent with a cross reactivity problem rather than any actual amphetamine exposure.
The labetalol prescribing information filed with the National Library of Medicine's drug label database does not list a drug test interaction as a formally labeled warning, which is typical for this kind of cross reactivity. It confirms the drug's identity and intended use for hypertension, including hypertensive emergencies where intravenous labetalol is used. You can view the current label on DailyMed, the National Library of Medicine's drug label repository.
Why this comes up most in obstetric and hospital settings
Labetalol is a first line choice for blood pressure control in pregnancy, and many hospitals run a urine drug panel as a routine part of labor and delivery admission or emergency evaluation. That means a patient who is taking labetalol exactly as prescribed can end up with an unconfirmed positive amphetamine screen in her chart at a moment when she and her care team are focused on something else entirely. An unconfirmed screening result should never be treated as proof of illicit stimulant use. The point of the two step process, screen then confirm, is specifically to catch cases like this before anyone acts on a result that chemistry alone cannot fully explain.
Screening immunoassay versus confirmation testing, side by side
| Feature | Initial immunoassay screen | Confirmation test (GC/MS or LC-MS/MS) |
|---|---|---|
| What it measures | Antibody binding to a drug class shape | The exact molecule present in the sample |
| Speed | Minutes, often point of care | Run in a certified laboratory, takes longer |
| Cross reactivity risk | Yes, certain medications and metabolites can trigger a positive | Very low, method identifies specific compounds |
| Appropriate use of a positive result | Preliminary only, not a final determination | Considered the definitive result for reporting purposes |
| Who typically reviews it | Ordering clinician or testing program | Medical review officer or ordering physician, with prescription history considered |
The medical review officer process and prescription documentation
In employment drug testing programs, a positive screening result is not reported as a final positive until a Medical Review Officer, or MRO, reviews it. The MRO is a licensed physician trained to interpret drug test results and to contact the person tested about any current prescriptions before a result is reported to an employer. If labetalol or another cross reacting medication explains an amphetamine screen, documentation such as a pharmacy record or a prescription label supports that review. Our overview of the MRO process for employers covers how that verification step works in more detail.
Outside of formal workplace testing programs, the same logic applies in a hospital setting. A treating clinician who sees an unexpected amphetamine positive should ask about current medications and, where there is doubt, order confirmation testing before documenting the result as significant. This is general information about how the testing process is supposed to work, not legal or medical guidance for a specific case, and any decision about a specific patient or employee should involve the treating clinician, the MRO, or counsel as appropriate.
Other beta blockers and the amphetamine panel
Labetalol is not the only cardiovascular medication associated with amphetamine class cross reactivity in the published literature. Our related post on propranolol and workplace drug panels looks at a different beta blocker and how it can interact with screening chemistry. The rule for any medication suspected of causing a cross reaction is the same: confirmation testing settles the question, and prescription documentation through the MRO or treating clinician is the correct channel, not a debate over the immunoassay result itself.
What a testing program or clinician should do with a positive screen
Federal guidance for workplace drug testing programs, maintained by the Substance Abuse and Mental Health Services Administration, sets out laboratory certification standards and the role of the Medical Review Officer in reviewing results before they are reported. You can see the program resources, including the mandatory guidelines and MRO manual, on the SAMHSA drug free workplace program page. The general principle that a federally regulated program follows, and that most employer and clinical programs model their own practice on, is that an initial positive screen is reviewed and, where appropriate, confirmed before it is treated as a final result or used to make a decision about a person.
For point of care testing with cups or dip cards that include an amphetamine panel, the practical takeaway is the same whether the setting is a hospital, a clinic, or a workplace program. Any positive amphetamine or methamphetamine result in a patient or employee with a labetalol prescription should be sent for confirmation testing rather than acted on immediately. Employers and clinics that use our drug test cups with amphetamine panels can pair point of care screening with lab confirmation through the same workflow used for any other presumptive positive.
What someone taking labetalol can do
- Tell the testing program, the collector, or the treating clinician about the labetalol prescription before or at the time of the test, if the setting allows it.
- Keep a current prescription label, pharmacy printout, or medication list available in case the MRO or clinician needs to verify it.
- If a screen comes back positive, ask whether the sample will go to confirmation testing before any decision is made, rather than assuming the screening result is final.
- Understand that a positive immunoassay is a preliminary flag, not a diagnosis of drug use, and that the confirmation step exists for exactly this kind of situation.
Frequently asked questions
Does labetalol show up as amphetamine or methamphetamine on a drug test?
Published case reports describe labetalol causing a positive result on the initial amphetamine immunoassay screen in some patients. Confirmation testing in those same cases did not detect actual amphetamine or methamphetamine, because labetalol itself is not an amphetamine.
Why does labetalol cause a false positive on an immunoassay screen?
Research on the chemistry behind this points to a labetalol metabolite with a structure close enough to the amphetamine class that it can bind the antibody used in some screening kits. This is a cross reactivity issue with the screening method, not evidence that amphetamine is present.
Will a confirmation test also show positive for labetalol?
No. Confirmation testing by GC/MS or LC-MS/MS identifies the exact molecule in the sample. If no amphetamine or methamphetamine is actually present, the confirmation test reports a negative result even after a positive screening immunoassay.
What should someone taking labetalol do if a drug screen comes back positive?
Provide documentation of the prescription to the Medical Review Officer or treating clinician and ask that the sample go through confirmation testing before any result is treated as final. This is the process the testing program is designed to follow.
Does labetalol affect other drug test panels besides amphetamines?
The published literature on labetalol centers on amphetamine and methamphetamine cross reactivity. Evidence connecting labetalol to false positives on other drug classes is limited, so any claim about other panels should be treated with caution until supported by a primary source.
Is labetalol itself a controlled substance?
No. Labetalol is a prescription blood pressure medication, not a controlled substance, and it is not related to amphetamines pharmacologically. The false positive issue is a laboratory cross reactivity problem with certain screening antibodies, not an indication that labetalol and amphetamines are the same type of drug.
This article is general information about drug test screening chemistry and is not legal or medical advice. Anyone with questions about a specific test result, prescription, or employment situation should talk with a qualified clinician, a Medical Review Officer, or an attorney.
